Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Associations of comorbidities and medications with COVID-19 outcome: A retrospective analysis of real-world evidence data

View ORCID ProfileBasel Abu-Jamous, Arseni Anisimovich, Janie Baxter, View ORCID ProfileLucy Mackillop, View ORCID ProfileMarcela P. Vizcaychipi, View ORCID ProfileAlex McCarthy, Rabia T. Khan
doi: https://doi.org/10.1101/2020.08.20.20174169
Basel Abu-Jamous
1Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Basel Abu-Jamous
Arseni Anisimovich
1Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janie Baxter
1Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucy Mackillop
1Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE
2Oxford University Hospitals NHS Foundation Trust, Women’s Centre, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
3Nuffield Department of Women’s and Reproductive Health, University of Oxford, Women’s Centre, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lucy Mackillop
Marcela P. Vizcaychipi
4Chelsea and Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
5Academic Department of Anaesthesia & Intensive Care Medicine, Imperial College London, Chelsea & Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcela P. Vizcaychipi
Alex McCarthy
4Chelsea and Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alex McCarthy
Rabia T. Khan
1Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rabia.khan@sensynehealth.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Hundreds of thousands of deaths have already been recorded for patients with the severe acute respiratory syndrome coronavirus (SARS-CoV-2; aka COVID-19). Understanding whether there is a relationship between comorbidities and COVID-19 positivity will not only impact clinical decisions, it will also allow an understanding of how better to define the long-term complications in the groups at risk. In turn informing national policy on who may benefit from more stringent social distancing and shielding strategies. Furthermore, understanding the associations between medications and certain outcomes may also further our understanding of indicators of vulnerability in people with COVID-19 and co-morbidities.

Methods Electronic healthcare records (EHR) from two London hospitals were analysed between 1st January and 27th May 2020. 5294 patients presented to the hospitals in whom COVID status was formally assessed; 1253 were positive for COVID-19 and 4041 were negative. This dataset was analysed to identify associations between comorbidities and medications, separately and two outcomes: (1) presentation with a COVID-19 positive diagnosis, and (2) inpatient death following COVID-19 positive diagnosis. Medications were analysed in different time windows of prescription to differentiate between short-term and long-term medications. All analyses were done with controls (without co-morbidity) matched for age, sex, and number of admissions, and a robustness approach was conducted to only accept results that consistently appear when the analysis is repeated with different proportions of the data.

Results We observed higher COVID-19 positive presentation for patients with hypertension (1.7 [1.3-2.1]) and diabetes (1.6 [1.2-2.1]). We observed higher inpatient COVID-19 mortality for patients with hypertension (odds ratio 2.7 [95% CI 1.9-3.9]), diabetes (2.2 [1.4-3.5]), congestive heart failure (3.1 [1.5-6.4]), and renal disease (2.6 [1.4-5.1]). We also observed an association with reduced COVID-19 mortality for diabetic patients for whom anticoagulants (0.11 [0.03-0.50]), lipid-regulating drugs (0.15 [0.04-0.58]), penicillins (0.20 [0.06-0.63]), or biguanides (0.19 [0.05-0.70]) were administered within 21 days after their positive COVID-19 test with no evidence that they were on them before, and for hypertensive patients for whom anticoagulants (0.08 [0.02-0.35]), antiplatelet drugs (0.10 [0.02-0.59]), lipid-regulating drugs (0.15 [0.05-0.46]), penicillins (0.14 [0.05-0.45]), or angiotensin-converting enzyme inhibitors (ARBs) (0.06 [0.01-0.53]) were administered within 21 days post-COVID-19-positive testing with no evidence that they were on them before. Moreover, long-term antidiabetic drugs were associated with reduced COVID-19 mortality in diabetic patients (0.26 [0.10-0.67]).

Conclusions We provided real-world evidence for observed associations between COVID-19 outcomes and a number of comorbidities and medications. These results require further investigation and replication in other data sets.

Competing Interest Statement

BAJ, AA, JB, LM, and RTK are employees of Sensyne Health plc (part-time in the case of LM) or were employed by Sensyne Health plc over the time period in which they contributed to this study. LM is further funded by The National Institute for Health Research Grant (IS-BRC-1215-20008).

Funding Statement

The study was supported by Sensyne Health plc. LM is further funded by The National Institute for Health Research Grant (IS-BRC-1215-20008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the IG management team of Sensyne Health plc and Chelsea & Westminster NHS Foundation Trust under the Strategic Research Agreement (SRA) and relative Data Sharing Agreements (DSAs) signed by the NHS Trust and Sensyne Health plc on 25th July 2018. All analyses were conducted on data with no personal identifying information. Therefore, informed consent was waived by the ethics committee of the Chelsea & Westminster NHS Foundation Trust, which provided ethical approval for the study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

_

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 23, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Associations of comorbidities and medications with COVID-19 outcome: A retrospective analysis of real-world evidence data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Associations of comorbidities and medications with COVID-19 outcome: A retrospective analysis of real-world evidence data
Basel Abu-Jamous, Arseni Anisimovich, Janie Baxter, Lucy Mackillop, Marcela P. Vizcaychipi, Alex McCarthy, Rabia T. Khan
medRxiv 2020.08.20.20174169; doi: https://doi.org/10.1101/2020.08.20.20174169
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Associations of comorbidities and medications with COVID-19 outcome: A retrospective analysis of real-world evidence data
Basel Abu-Jamous, Arseni Anisimovich, Janie Baxter, Lucy Mackillop, Marcela P. Vizcaychipi, Alex McCarthy, Rabia T. Khan
medRxiv 2020.08.20.20174169; doi: https://doi.org/10.1101/2020.08.20.20174169

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)